Cell and Gene Therapy Investment Trends: Strategic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2950
Buy Report Download FREE Resources

Published: December 01, 2025 Report Code: GDHCHT654-TH

Select Item

Explore the cell and gene therapy (CGT) investment landscape with GlobalData’s market analysis. Analyze venture capital activity, licensing deals, M&A trends, commercial therapies, platform technologies, and investment opportunities shaping the CGT market through 2031.

Report Value Proposition – Why Does the Cell & Gene Therapy Investment Landscape Matter?

Cell and gene therapies (CGTs) are transforming the treatment of genetic diseases, oncology, hematological disorders, and neurological conditions, creating one of the most dynamic areas of biopharmaceutical innovation. As the market matures, investors are shifting their focus toward scalable technologies, manufacturing capabilities, platform innovation, and commercially viable therapeutic programs.

GlobalData’s Cell & Gene Therapy Investment Trends report provides a comprehensive analysis of the evolving CGT investment landscape, examining venture capital activity, licensing agreements, mergers and acquisitions, strategic partnerships, and the technologies attracting the greatest investor interest.

You can use this report to:

  • Understand investment trends across the global CGT market
  • Analyze venture capital, licensing, and M&A activity
  • Identify high-growth therapeutic areas and technology platforms
  • Evaluate investor sentiment and funding priorities
  • Benchmark leading pharmaceutical companies and emerging biotech innovators
  • Support strategic planning, business development, and investment decisions

Built on GlobalData’s pharmaceutical intelligence and industry expertise, this report helps organizations navigate the rapidly evolving cell and gene therapy ecosystem.

Key Insights in the Cell & Gene Therapy Investment Landscape

The report examines the commercial and investment trends driving the next phase of growth across the CGT market.

Key themes include:

  • Venture capital investment trends across cell and gene therapies
  • Licensing, partnership, and merger & acquisition activity
  • Growing investment in scalable platform technologies and manufacturing capabilities
  • Investor focus on vector engineering, cell engineering, and allogeneic therapies
  • Expansion beyond rare diseases into oncology, neurology, cardiovascular, and metabolic disorders
  • Manufacturing, regulatory, reimbursement, and commercialization challenges
  • Strategic priorities shaping pharmaceutical investment and platform acquisition

Scope

What Will You Learn from This Cell & Gene Therapy Investment Report?

This report provides insight into:

  • Global CGT investment trends

  • Venture capital funding activity

  • Licensing and M&A landscape

  • High-growth therapeutic areas

  • Platform and technology innovation

  • Pharmaceutical partnership strategies

  • Manufacturing and commercialization challenges

  • Regulatory and reimbursement considerations

  • Competitive positioning across the CGT market

  • Market outlook through 2031

Who Should Buy This Report?

This report is valuable for:

  • Biopharmaceutical companies

  • Biotechnology startups

  • Venture capital firms

  • Private equity investors

  • Business development and licensing teams

  • R&D and innovation leaders

  • Strategy and corporate development teams

  • Healthcare consultants

  • Market intelligence professionals

  • Investment analysts

How Companies Use This Cell & Gene Therapy Investment Analysis

Biopharmaceutical companies use this report to identify partnership opportunities, prioritize R&D investments, and strengthen commercialization strategies across the CGT landscape.

Business development teams leverage the analysis to evaluate licensing opportunities, acquisition targets, and emerging platform technologies.

Investors, consultants, and strategy teams use the report to monitor funding activity, benchmark competitive positioning, and identify long-term growth opportunities within the rapidly evolving CGT market.

Reasons to Buy

Benchmark the Cell & Gene Therapy Market Against Leading Investment Trends

This report helps organizations benchmark investment activity, platform innovation, and competitive strategies across the global cell and gene therapy industry.

It provides comparative insight into:

  • Venture capital investment

  • Licensing and partnership activity

  • M&A trends

  • Platform technologies

  • Therapeutic focus areas

  • Commercial growth opportunities

As a result, organizations can better evaluate investment priorities and position themselves for long-term success within the CGT sector.

Built on Trusted GlobalData Pharmaceutical Intelligence

GlobalData’s Cell & Gene Therapy Investment Trends report is built on proprietary pharmaceutical databases, biotechnology intelligence, and extensive industry research.

Trusted by pharmaceutical companies, biotechnology firms, investors, and healthcare advisors, GlobalData delivers actionable intelligence that supports investment evaluation, business development, and strategic planning.

GlobalData’s analysts provide deep expertise across cell therapy, gene therapy, biotechnology, venture funding, licensing, and pharmaceutical innovation.

Identify the Next Wave of Growth in Cell & Gene Therapies

As investment continues to shift toward scalable platforms, advanced manufacturing, and commercially viable therapies, organizations that understand emerging funding trends and competitive dynamics will be better positioned to capture opportunities across the evolving global cell and gene therapy market through 2031.

Table of Contents

Executive Summary

Introduction

CGT Approvals and Reimbursement Landscape

Venture Capital Financing for CGTs

M&A and Licensing Deals for CGTs

CGT Catalysts

Key Takeaways

Appendix –

– Abbreviations

– Related Reports

– Authors

– Contact Us

Cell and Gene Therapy Investment Trends: Strategic Intelligence thematic reports
Currency USD
$2,950

Can be used by individual purchaser only

Most Popular
$5,900

Can be shared by unlimited users within one corporate location e.g. a regional office

$8,850

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Cell and Gene Therapy Investment Trends: Strategic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Gene Therapy reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Cell and Gene Therapy Investment Trends: Strategic Intelligence in real time.

  • Access a live Cell and Gene Therapy Investment Trends: Strategic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more